Poolbeg Pharma PLC (AIM:POLB)'s Jeremy Skillington and Cathal Friel present news of their signed option agreement to licence a vaccine for an infectious disease called melioidosis.
Poolbeg has signed the agreement for MelioVac with University College Dublin and its inventor, associate professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.
It allows the group to carry on its due diligence on the preclinical asset, which is the recipient of a Wellcome Trust award to aid its development, as well as five other potential vaccine candidates discovered by McClean and her team.